• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

寡核苷酸跨Caco-2单层的递送:自乳化药物递送系统(SEDDS)的设计与评价

Oligonucleotide Delivery across the Caco-2 Monolayer: The Design and Evaluation of Self-Emulsifying Drug Delivery Systems (SEDDS).

作者信息

Kubackova Jana, Holas Ondrej, Zbytovska Jarmila, Vranikova Barbora, Zeng Guanghong, Pavek Petr, Mullertz Anette

机构信息

Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Faculty of Chemical Technology, University of Chemistry and Technology Prague, Technicka 5, 166 28 Prague, Czech Republic.

出版信息

Pharmaceutics. 2021 Mar 28;13(4):459. doi: 10.3390/pharmaceutics13040459.

DOI:10.3390/pharmaceutics13040459
PMID:33800701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8066367/
Abstract

Oligonucleotides (OND) represent a promising therapeutic approach. However, their instability and low intestinal permeability hamper oral bioavailability. Well-established for oral delivery, self-emulsifying drug delivery systems (SEDDS) can overcome the weakness of other delivery systems such as long-term instability of nanoparticles or complicated formulation processes. Therefore, the present study aims to prepare SEDDS for delivery of a nonspecific fluorescently labeled OND across the intestinal Caco-2 monolayer. The hydrophobic ion pairing of an OND and a cationic lipid served as an effective hydrophobization method using either dimethyldioctadecylammonium bromide (DDAB) or 1,2-dioleoyl-3-trimethylammonium propane (DOTAP). This strategy allowed a successful loading of OND-cationic lipid complexes into both negatively charged and neutral SEDDS. Subjecting both complex-loaded SEDDS to a nuclease, the negatively charged SEDDS protected about 16% of the complexed OND in contrast to 58% protected by its neutral counterpart. Furthermore, both SEDDS containing permeation-enhancing excipients facilitated delivery of OND across the intestinal Caco-2 cell monolayer. The negatively charged SEDDS showed a more stable permeability profile over 120 min, with a permeability of about 2 × 10 cm/s, unlike neutral SEDDS, which displayed an increasing permeability reaching up to 7 × 10 cm/s. In conclusion, these novel SEDDS-based formulations provide a promising tool for OND protection and delivery across the Caco-2 cell monolayer.

摘要

寡核苷酸(OND)是一种很有前景的治疗方法。然而,它们的不稳定性和低肠道渗透性阻碍了口服生物利用度。自乳化药物递送系统(SEDDS)在口服给药方面已得到充分确立,它可以克服其他递送系统的缺点,如纳米颗粒的长期不稳定性或复杂的制剂工艺。因此,本研究旨在制备用于将非特异性荧光标记的OND穿过肠道Caco-2单层细胞的SEDDS。使用二甲基二辛基溴化铵(DDAB)或1,2-二油酰基-3-三甲基铵丙烷(DOTAP),将OND与阳离子脂质进行疏水离子配对作为一种有效的疏水化方法。该策略成功地将OND-阳离子脂质复合物负载到带负电荷和中性的SEDDS中。将两种负载复合物的SEDDS用核酸酶处理后,带负电荷的SEDDS保护了约16%的复合OND,而其对应的中性SEDDS保护了58%。此外,两种含有渗透促进辅料的SEDDS都促进了OND穿过肠道Caco-2细胞单层。与中性SEDDS不同,带负电荷的SEDDS在120分钟内显示出更稳定的渗透率曲线,渗透率约为2×10 cm/s,而中性SEDDS的渗透率则不断增加,最高可达7×10 cm/s。总之,这些基于SEDDS的新型制剂为OND在Caco-2细胞单层上的保护和递送提供了一种有前景的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/b7c79a133138/pharmaceutics-13-00459-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/45c1f2be549e/pharmaceutics-13-00459-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/2b12ab8b9d0c/pharmaceutics-13-00459-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/5b3ae9d243de/pharmaceutics-13-00459-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/4747d892854a/pharmaceutics-13-00459-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/7fa005d638c5/pharmaceutics-13-00459-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/5469acbba572/pharmaceutics-13-00459-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/55900c5fa52f/pharmaceutics-13-00459-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/bff5b868df44/pharmaceutics-13-00459-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/c43a0c3bb739/pharmaceutics-13-00459-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/b7c79a133138/pharmaceutics-13-00459-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/45c1f2be549e/pharmaceutics-13-00459-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/2b12ab8b9d0c/pharmaceutics-13-00459-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/5b3ae9d243de/pharmaceutics-13-00459-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/4747d892854a/pharmaceutics-13-00459-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/7fa005d638c5/pharmaceutics-13-00459-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/5469acbba572/pharmaceutics-13-00459-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/55900c5fa52f/pharmaceutics-13-00459-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/bff5b868df44/pharmaceutics-13-00459-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/c43a0c3bb739/pharmaceutics-13-00459-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d3/8066367/b7c79a133138/pharmaceutics-13-00459-g010.jpg

相似文献

1
Oligonucleotide Delivery across the Caco-2 Monolayer: The Design and Evaluation of Self-Emulsifying Drug Delivery Systems (SEDDS).寡核苷酸跨Caco-2单层的递送:自乳化药物递送系统(SEDDS)的设计与评价
Pharmaceutics. 2021 Mar 28;13(4):459. doi: 10.3390/pharmaceutics13040459.
2
Development and in vitro evaluation of zeta potential changing self-emulsifying drug delivery systems for enhanced mucus permeation.发展和体外评价zeta 电位变化自乳化药物传递系统,以增强黏液渗透。
Int J Pharm. 2016 Aug 20;510(1):255-62. doi: 10.1016/j.ijpharm.2016.06.045. Epub 2016 Jun 18.
3
Oral self-emulsifying delivery systems for systemic administration of therapeutic proteins: science fiction?口服自乳化给药系统用于治疗性蛋白的全身给药:科幻小说?
J Drug Target. 2019 Nov;27(9):1017-1024. doi: 10.1080/1061186X.2019.1584200. Epub 2019 Jul 17.
4
Mucolytic self-emulsifying drug delivery systems (SEDDS) containing a hydrophobic ion-pair of proteinase.含有蛋白酶疏水离子对的黏液溶解型自乳化药物递送系统(SEDDS)
Eur J Pharm Sci. 2021 Jul 1;162:105658. doi: 10.1016/j.ejps.2020.105658. Epub 2020 Dec 1.
5
Multicomponent self nano emulsifying delivery systems of resveratrol with enhanced pharmacokinetics profile.多组分白藜芦醇自微乳给药系统及其增强的药代动力学特征。
Eur J Pharm Sci. 2019 Sep 1;137:105011. doi: 10.1016/j.ejps.2019.105011. Epub 2019 Jul 19.
6
Development and in vitro characterization of a papain loaded mucolytic self-emulsifying drug delivery system (SEDDS).载木瓜蛋白酶的黏液溶解型自乳化药物递送系统(SEDDS)的研发及体外特性研究
Int J Pharm. 2017 Sep 15;530(1-2):346-353. doi: 10.1016/j.ijpharm.2017.08.059. Epub 2017 Aug 3.
7
Phosphorylated PEG-emulsifier: Powerful tool for development of zeta potential changing self-emulsifying drug delivery systems (SEDDS).磷酸化聚乙二醇乳化剂:改变自乳化药物传递系统(SEDDS)ζ 电位的有力工具。
Eur J Pharm Biopharm. 2020 May;150:77-86. doi: 10.1016/j.ejpb.2020.03.004. Epub 2020 Mar 6.
8
Enhancing Oral Bioavailability of Domperidone Maleate: Formulation, Permeability Evaluation In-caco-2 Cell Monolayers and Rat Intestinal Permeability Studies.马来酸多潘立酮的口服生物利用度增强:制剂、Caco-2 细胞单层渗透评估和大鼠肠道渗透研究。
Curr Drug Deliv. 2024;21(7):1010-1023. doi: 10.2174/1567201820666230214091509.
9
Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity.槲皮素新型自乳化制剂增强体内抗氧化潜力:对药物诱导的心脏毒性和肾毒性的影响。
Free Radic Biol Med. 2013 Dec;65:117-130. doi: 10.1016/j.freeradbiomed.2013.05.041. Epub 2013 Jun 19.
10
Improved Intestinal Mucus Permeation of Vancomycin via Incorporation Into Nanocarrier Containing Papain-Palmitate.通过将万古霉素纳入含有木瓜蛋白酶-棕榈酸的纳米载体中,提高了其肠道黏膜通透性。
J Pharm Sci. 2019 Oct;108(10):3329-3339. doi: 10.1016/j.xphs.2019.05.020. Epub 2019 May 25.

引用本文的文献

1
Hydrophobic Ion Pairing of Polymyxin B with Oleic Acid: A Dissipative Particle Dynamics Simulation Study.多粘菌素B与油酸的疏水离子对作用:耗散粒子动力学模拟研究
Pharmaceutics. 2025 Apr 27;17(5):574. doi: 10.3390/pharmaceutics17050574.
2
Potential of the Nano-Encapsulation of Antioxidant Molecules in Wound Healing Applications: An Innovative Strategy to Enhance the Bio-Profile.抗氧化分子纳米封装在伤口愈合应用中的潜力:一种增强生物特性的创新策略。
Molecules. 2025 Jan 31;30(3):641. doi: 10.3390/molecules30030641.
3
Innovations in Nanoemulsion Technology: Enhancing Drug Delivery for Oral, Parenteral, and Ophthalmic Applications.

本文引用的文献

1
Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans.肠道渗透增强剂提高大分子的口服生物利用度:在人体中低疗效的原因。
Expert Opin Drug Deliv. 2021 Feb;18(2):273-300. doi: 10.1080/17425247.2021.1825375. Epub 2020 Sep 29.
2
Coexistence of oil droplets and lipid vesicles in propofol drug products.丙泊酚药物制剂中油滴和脂质体的共存。
Int J Pharm. 2020 Mar 15;577:118998. doi: 10.1016/j.ijpharm.2019.118998. Epub 2020 Jan 11.
3
Nanomaterials for direct and indirect immunomodulation: A review of applications.
纳米乳剂技术的创新:增强口服、肠胃外和眼科应用的药物递送
Pharmaceutics. 2024 Oct 17;16(10):1333. doi: 10.3390/pharmaceutics16101333.
4
Nanocarriers for delivery of siRNA as gene silencing mediator.用于递送作为基因沉默介质的小干扰RNA的纳米载体。
EXCLI J. 2022 Aug 1;21:1028-1052. doi: 10.17179/excli2022-4975. eCollection 2022.
5
Formulation and Evaluation of Self-Nanoemulsifying Drug Delivery System Derived Tablet Containing Sertraline.含舍曲林的自纳米乳化药物递送系统衍生片剂的制剂与评价
Pharmaceutics. 2022 Jan 31;14(2):336. doi: 10.3390/pharmaceutics14020336.
6
Sorafenib Repurposing for Ophthalmic Delivery by Lipid Nanoparticles: A Preliminary Study.索拉非尼经脂质纳米粒用于眼部给药的重新利用:一项初步研究。
Pharmaceutics. 2021 Nov 18;13(11):1956. doi: 10.3390/pharmaceutics13111956.
7
Preclinical Evaluation of Lipid-Based Nanosystems.基于脂质的纳米系统的临床前评估。
Pharmaceutics. 2021 May 12;13(5):708. doi: 10.3390/pharmaceutics13050708.
纳米材料的直接和间接免疫调节作用:应用综述。
Eur J Pharm Sci. 2020 Jan 15;142:105139. doi: 10.1016/j.ejps.2019.105139. Epub 2019 Nov 5.
4
Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies.Labrasol® 是一种有效的肠道渗透增强剂,可穿过大鼠肠道:离体和在体大鼠研究。
J Control Release. 2019 Sep 28;310:115-126. doi: 10.1016/j.jconrel.2019.08.008. Epub 2019 Aug 8.
5
Fenofibrate oral absorption from SNEDDS and super-SNEDDS is not significantly affected by lipase inhibition in rats.脂肪酶抑制对大鼠 SNEDDS 和超 SNEDDS 中非诺贝特口服吸收的影响不显著。
Eur J Pharm Biopharm. 2019 Sep;142:258-264. doi: 10.1016/j.ejpb.2019.07.002. Epub 2019 Jul 2.
6
In vitro digestion models to evaluate lipid based drug delivery systems; present status and current trends.用于评价基于脂质的药物传递系统的体外消化模型;现状和当前趋势。
Adv Drug Deliv Rev. 2019 Mar 1;142:35-49. doi: 10.1016/j.addr.2019.06.010. Epub 2019 Jun 29.
7
Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?口服非病毒核酸类治疗药物——我们有这个胆量吗?
Eur J Pharm Sci. 2019 May 15;133:190-204. doi: 10.1016/j.ejps.2019.03.027. Epub 2019 Apr 1.
8
SEDDS for intestinal absorption of insulin: Application of Caco-2 and Caco-2/HT29 co-culture monolayers and intra-jejunal instillation in rats.固体脂质分散体(SEDDS)促进胰岛素的肠道吸收:Caco-2 和 Caco-2/HT29 共培养单层以及在大鼠空肠内灌注的应用。
Int J Pharm. 2019 Apr 5;560:377-384. doi: 10.1016/j.ijpharm.2019.02.014. Epub 2019 Feb 18.
9
Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update.渗透促进剂在大分子口服给药中的应用:最新进展
Pharmaceutics. 2019 Jan 19;11(1):41. doi: 10.3390/pharmaceutics11010041.
10
SEDDS: A game changing approach for the oral administration of hydrophilic macromolecular drugs.SEDDS:一种用于口服亲水大分子药物的颠覆性方法。
Adv Drug Deliv Rev. 2019 Mar 1;142:91-101. doi: 10.1016/j.addr.2018.07.001. Epub 2018 Jul 4.